Relative performance of brivaracetam as adjunctive treatment of focal seizures in adults: a network meta-analysis

References

• Laxer KD, Trinka E, Hirsch LJ, et al. The consequences of refractory epilepsy and its treatment. Epilepsy Behav. 2014;37:59–70.
   PubMed Web of Science ®Google Scholar
• Gillard M, Fuks B, Leclercq K, et al. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol. 2011;664:36–44.
   PubMed Web of Science ®Google Scholar
• NICE. Guide to the methods of technology appraisal [Internet]. 2013 [cited 2016 Apr 4]. Available from: https://www.nice.org.uk/article/pmg9/chapter/Foreword.
   Google Scholar
• Brodie MJ. Meta-analyses of antiepileptic drugs for refractory partial (focal) epilepsy: an observation. Br J Clin Pharmacol. 2013;76:630–631.
   PubMed Web of Science ®Google Scholar
• Walker MC, Sander JW. Difficulties in extrapolating from clinical trial data to clinical practice: the case of antiepileptic drugs. Neurology. 1997;49:333–337.
   PubMed Web of Science ®Google Scholar
• Zaccara G, Giovannelli F, Bell GS, et al. Network meta-analyses of antiepileptic drug efficacy and tolerability in drug-resistant focal epilepsies: a clinical perspective. Eur J Clin Pharmacol. 2014;70:647–654.
   PubMed Web of Science ®Google Scholar
• Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011;14:417–428.
   PubMed Web of Science ®Google Scholar
• Dias S, Sutton AJ, Ades AE, et al. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33:607–617.
   PubMed Web of Science ®Google Scholar
• Dias S, Welton NJ, Sutton AJ, et al. Evidence synthesis for decision making 5: the baseline natural history model. Med Decis Making. 2013;33:657–670.
   PubMed Web of Science ®Google Scholar
• Lunn DJ, Thomas A, Best N, et al. WinBUGS – a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput. 2000;10:325–337.
   Web of Science ®Google Scholar
• R Core Team. R: a language and environment for statistical computing. Vienna (Austria): R Foundation for Statistical Computing; 2013.
   Google Scholar
• Brooks SP, Gelman A. Alternative methods for monitoring convergence of iterative simulations. J Comput Graph Stat. 1998;7:434–455.
   Web of Science ®Google Scholar
• Woodward P. Bayesian analysis made simple: an Excel GUI for WinBUGS. Boca Raton, FL: Chapman & Hall/CRC Biostatistics Series; 2012.
   Google Scholar
• Dias S, Welton NJ, Sutton AJ, et al. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making. 2013;33:641–656.
   PubMed Web of Science ®Google Scholar
• NICE. Specification for manufacturer/sponsor submission of evidence [Internet]. 2012 [cited 2017 Sep 20]. Available from: http://www.nice.org.uk/aboutnice/howwework/devnicetech/SpecificationForManufacturerSponsorSubmissionOfEvidence.jsp.
   Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration; 2011.
   Google Scholar
• Bodalia PN, Grosso AM, Sofat R, et al. Comparative efficacy and tolerability of anti-epileptic drugs for refractory focal epilepsy: systematic review and network meta-analysis reveals the need for long term comparator trials. Br J Clin Pharmacol. 2013;76:649–667.
   PubMed Web of Science ®Google Scholar
• Hemery C, Ryvlin P, Rheims S. Prevention of generalized tonic–clonic seizures in refractory focal epilepsy: a meta-analysis. Epilepsia. 2014;55:1789–1799.
   PubMed Web of Science ®Google Scholar
• Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. Epilepsia. 2010;51:7–26.
   PubMed Web of Science ®Google Scholar
• Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern nonenzyme-inducing AEDs for refractory focal epilepsy: systematic review and meta-analysis. Epilepsia. 2012;53:512–520.
   PubMed Web of Science ®Google Scholar
• Rheims S, Perucca E, Cucherat M, et al. Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. Epilepsia. 2011;52:219–233.
   PubMed Web of Science ®Google Scholar
• Zaccara G, Giovannelli F, Maratea D, et al. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine. Seizure. 2013;22:528–536.
   PubMed Web of Science ®Google Scholar
• Costa J, Fareleira F, Ascencao R, et al. Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis. Epilepsia. 2011;52:1280–1291.
   PubMed Web of Science ®Google Scholar
• Gao L, Xia L, Zhao FL, et al. Clinical efficacy and safety of the newer antiepileptic drugs as adjunctive treatment in adults with refractory partial-onset epilepsy: a meta-analysis of randomized placebo-controlled trials. Epilepsy Res. 2013;103:31–44.
   PubMed Web of Science ®Google Scholar
• Khan N, Shah D, Tongbram V, et al. The efficacy and tolerability of perampanel and other recently approved anti-epileptic drugs for the treatment of refractory partial onset seizure: a systematic review and Bayesian network meta-analysis. Curr Med Res Opin. 2013;29:1001–1013.
   PubMed Web of Science ®Google Scholar
• Martyn-St James M, Glanville J, McCool R, et al. The efficacy and safety of retigabine and other adjunctive treatments for refractory partial epilepsy: a systematic review and indirect comparison. Seizure. 2012;21:665–678.
   PubMed Web of Science ®Google Scholar
• Borghs S, Thieffry S, Noack-Rink M, et al. Health care cost associated with the use of enzyme-inducing and non-enzyme-active antiepileptic drugs in the UK: a long-term retrospective matched cohort study. BMC Neurol. 2017;17:59.
   PubMed Web of Science ®Google Scholar
• Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369:1000–1015.
   PubMed Web of Science ®Google Scholar
• NICE. Epilepsies: diagnosis and management (CG137) [Internet]. 2012 [cited 2017 Mar 7]. Available from: https://www.nice.org.uk/guidance/cg137.
   Google Scholar
• Swallow E, Fang A, Signorovitch J, et al. Can matching-adjusted indirect comparison methods mitigate placebo response differences among patient populations in adjunctive trials of brivaracetam and levetiracetam? CNS Drugs. 2017;31:899–910.
   PubMed Web of Science ®Google Scholar
• French JA, England JD. Invited article: comparative effectiveness research, evidence-based medicine, and the AAN. Neurology. 2010;75:562–567.
   PubMed Web of Science ®Google Scholar
• Luoni C, Bisulli F, Canevini MP, et al. Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. Epilepsia. 2011;52:2181–2191.
   PubMed Web of Science ®Google Scholar
• Zaccara G, Sisodiya SM, Giovannelli F, et al. Network meta-analysis and the comparison of efficacy and tolerability of anti-epileptic drugs for treatment of refractory focal epilepsy. Br J Clin Pharmacol. 2013;76:827–828.
   PubMed Web of Science ®Google Scholar